.Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX02_Riluzole.Riluzole

Information

Riluzole is an oral glutamate release inhibitor used primarily for the treatment of amyotrophic lateral sclerosis (ALS). It slows disease progression and prolongs survival in ALS patients. Riluzole is approved for clinical use in multiple countries including the US and EU.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after single oral dosing.

References

1. Brooks, BR, et al., & Cazzaniga, S (2019). Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Clinical therapeutics 41(12) 2490–2499. DOI:10.1016/j.clinthera.2019.09.016 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31635890

2. Sarkar, M, et al., & Chow, DS (2018). Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 125 1–10. DOI:10.1016/j.ejps.2018.09.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30201516

3. Bireley, JD, & Morren, JA (2023). CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS). Expert opinion on investigational drugs 32(8) 677–683. DOI:10.1080/13543784.2023.2252738 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37642362

Revisions

• 06/2025 initial generated model